Orthofix International NV (NASDAQ:OFIX) traded down 1.3% on Wednesday . The stock traded as low as $43.01 and last traded at $43.58, with a volume of 72,318 shares traded. The stock had previously closed at $44.17.
Several equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Orthofix International NV from a “hold” rating to a “strong-buy” rating and set a $49.00 target price on the stock in a report on Thursday, August 4th. TheStreet lowered shares of Orthofix International NV from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd.
The stock’s market cap is $789.84 million. The firm has a 50 day moving average of $43.83 and a 200-day moving average of $43.70.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/orthofix-international-nv-ofix-stock-price-down-1-3.html
Orthofix International NV (NASDAQ:OFIX) last announced its quarterly earnings results on Monday, August 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.08. The company had revenue of $104.10 million for the quarter, compared to analyst estimates of $102.40 million. Orthofix International NV had a negative net margin of 0.37% and a positive return on equity of 8.50%. The firm’s revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.36 EPS. Equities research analysts anticipate that Orthofix International NV will post $1.41 EPS for the current year.
In related news, insider Michael Finegan sold 25,000 shares of Orthofix International NV stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $45.16, for a total transaction of $1,129,000.00. Following the sale, the insider now directly owns 51,670 shares of the company’s stock, valued at approximately $2,333,417.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 5.10% of the company’s stock.
Several large investors have recently made changes to their positions in OFIX. Renaissance Technologies LLC raised its stake in shares of Orthofix International NV by 78.7% in the first quarter. Renaissance Technologies LLC now owns 456,379 shares of the medical device company’s stock valued at $18,949,000 after buying an additional 201,020 shares during the period. TIAA CREF Investment Management LLC raised its stake in shares of Orthofix International NV by 4.7% in the first quarter. TIAA CREF Investment Management LLC now owns 95,843 shares of the medical device company’s stock valued at $3,979,000 after buying an additional 4,269 shares during the period. DIAM Co. Ltd. raised its stake in shares of Orthofix International NV by 19.3% in the second quarter. DIAM Co. Ltd. now owns 26,065 shares of the medical device company’s stock valued at $1,105,000 after buying an additional 4,214 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Orthofix International NV by 59.7% in the first quarter. Goldman Sachs Group Inc. now owns 65,550 shares of the medical device company’s stock valued at $2,721,000 after buying an additional 24,513 shares during the period. Finally, GSA Capital Partners LLP raised its stake in shares of Orthofix International NV by 66.2% in the second quarter. GSA Capital Partners LLP now owns 82,612 shares of the medical device company’s stock valued at $3,503,000 after buying an additional 32,920 shares during the period. 91.26% of the stock is currently owned by institutional investors.
About Orthofix International NV
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International NV Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Orthofix International NV and related companies with MarketBeat.com’s FREE daily email newsletter.